Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial

Study limitation reported by the research below: “The 'practice changing' impact flag is applied cautiously — this is a single-arm trial without a randomized comparator; cross-trial comparisons should be interpreted carefully.”